Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224780 | 1.00 | SAT1 (0.50) | SAT1GRM1JAK2JAK1TYK2 | |
| SCHEMBL24080019 | 0.89 | SAT1 (0.40) | SAT1GRM1MEN1KMT2ADAO | |
| SCHEMBL124276 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL28865713 | 0.81 | SAT1 (0.62) | SAT1JAK2JAK1TYK2MEN1 | |
| Hydrochloric Acid SCHEMBL5395476 | 0.81 | — | — | |
| SCHEMBL24129485 | 0.80 | SAT1 (0.38) | SAT1 | |
| SCHEMBL25994335 | 0.80 | SAT1 (0.38) | SAT1 | |
| SCHEMBL20871850 | 0.79 | SAT1 (0.42) | SAT1JAK2JAK1TYK2DAO | |
| SCHEMBL23505958 | 0.77 | DAO (0.33) | SAT1DAO | |
| SCHEMBL19698519 | 0.77 | SAT1 (0.58) | SAT1JAK2JAK1TYK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| CN-101389606-A | Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (CETP) | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| EP-1968941-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | SAT1 322/4885GRM1 4869/4885JAK2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.